Nurix insider sells 1,452 shares under 10b5-1 plan
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Nurix Therapeutics insider Gwenn Hansen sold 1,452 shares for $36,300, cutting her holdings by 1.22% under a pre-arranged Rule 10b5-1 plan. The sale follows other similar insider transactions, but Nurix reported quarterly earnings that significantly beat analyst expectations and holds a Moderate Buy consensus with a $34.64 average price target.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.